What Is Retatrutide? Everything You Need to Know in 2026

You've probably heard the names Ozempic and Mounjaro by now. These weight loss medications have been all over the news, changing how we think about treating obesity. But there's a new drug in the pipeline that could be even more effective than both of them, and it's called retatrutide.

If you've come across this name and want to understand what it actually is, you're in the right place. We're going to break down everything about retatrutide in plain language: what it is, how it works, what the research shows, and when you might be able to get it.

Retatrutide: The Basics

Retatrutide is an experimental weight loss medication being developed by Eli Lilly, the same pharmaceutical company behind Mounjaro and Zepbound (tirzepatide). It's given as a once-weekly injection, just like the weight loss drugs you may already be familiar with.

What makes retatrutide special is that it's what scientists call a "triple receptor agonist" or "tri-agonist." That might sound complicated, but the concept is actually pretty straightforward, and we'll explain it in a moment.

First, a few quick facts:

Generic name: Retatrutide
Development code: LY3437943
Manufacturer: Eli Lilly and Company
Drug class: Triple hormone receptor agonist (GLP-1/GIP/glucagon)
Administration: Once-weekly subcutaneous injection
Current status: Phase 3 clinical trials (not yet FDA approved)
Brand name: Not yet announced (will be named if/when approved)

How Does Retatrutide Work? A Simple Explanation

To understand retatrutide, it helps to first understand the drugs that came before it.

Generation 1: GLP-1 Drugs (Semaglutide/Ozempic/Wegovy)

The first major breakthrough in weight loss medication came from drugs that mimic a hormone called GLP-1 (glucagon-like peptide-1). Your body naturally makes GLP-1 in your gut after you eat. It does a few things:

Tells your brain you're full
Slows down digestion so food stays in your stomach longer
Helps control blood sugar

Semaglutide (sold as Ozempic for diabetes and Wegovy for weight loss) works by mimicking GLP-1, but in a much stronger and longer-lasting way than your body's natural version. The result? People eat less, feel satisfied sooner, and lose an average of about 15% of their body weight.

Generation 2: Dual Agonists (Tirzepatide/Mounjaro/Zepbound)

Then came tirzepatide, which Eli Lilly developed. Instead of targeting just one hormone receptor, tirzepatide targets two:

GLP-1: All the appetite-suppressing benefits described above
GIP (glucose-dependent insulinotropic polypeptide): Another gut hormone that improves how your body handles insulin and may help shift where your body stores fat

By hitting two targets instead of one, tirzepatide produces better results than semaglutide alone, with average weight loss of about 22.5% in clinical trials.

Generation 3: Triple Agonists (Retatrutide)

Now we get to retatrutide. It takes the dual-agonist approach one step further by adding a third target:

GLP-1: Reduces appetite, slows digestion
GIP: Improves insulin function, aids metabolic health
Glucagon: Increases calorie burning and fat breakdown

The glucagon piece is what makes retatrutide truly different. While GLP-1 and GIP mainly work by making you eat less (the "calories in" side), glucagon works by making your body burn more calories (the "calories out" side).

Think of it like this: previous drugs were good at turning down your appetite. Retatrutide does that too, but it also turns up your body's calorie-burning furnace. Attacking the problem from both sides simultaneously is why the results have been so impressive.

Why Is Eli Lilly Developing Retatrutide?

You might wonder why Eli Lilly would develop a new drug when they already have a successful one in tirzepatide. The answer is simple: there's still room for improvement.

Even with tirzepatide's impressive results, not everyone reaches their weight loss goals. Some patients plateau before reaching a healthy weight. And obesity-related diseases like type 2 diabetes, fatty liver disease, and cardiovascular disease continue to affect hundreds of millions of people worldwide.

Eli Lilly recognized that the glucagon receptor was an untapped opportunity. Their research team developed retatrutide as a single molecule that could activate all three receptors in one weekly injection. The goal was to create a more complete metabolic treatment that could help more people achieve clinically meaningful weight loss.

Eli Lilly has also been strategically building a portfolio of weight management medications. They already have:

Mounjaro/Zepbound (tirzepatide): Their currently approved dual agonist
Orforglipron: An oral GLP-1 drug in development (a pill instead of an injection)
Retatrutide: Their next-generation triple agonist

This gives them options to serve different patient needs and preferences.

What Do the Clinical Trials Show?

The research results for retatrutide have been turning heads across the medical community. Let's look at what the trials have found.

Phase 2 Trial: The First Big Signal

The Phase 2 trial was the first large study of retatrutide in people with obesity. Published in the New England Journal of Medicine in 2023, it included 338 adults and lasted 48 weeks.

The results were striking:

People taking the highest dose (12 mg) lost an average of 24.2% of their body weight
People taking the middle dose (8 mg) lost an average of 22.8%
People taking a lower dose (4 mg) lost an average of 17.5%
People taking a placebo (inactive injection) lost just 2.1%

What does 24.2% mean in real terms? If you weigh 220 pounds, that's about 53 pounds lost in less than a year. That's a life-changing amount of weight loss.

Even more encouraging: the weight loss curves in the trial were still trending downward at 48 weeks. In other words, people were still losing weight when the study ended, suggesting even greater losses might happen with longer treatment.

Phase 3 TRIUMPH-4 Trial: Even Better Results

The Phase 3 program for retatrutide is called TRIUMPH (Triple Hormone Receptor Agonist Initiated in Participants with Unhealthy Weight for a Multi-faceted Program of Health). It includes several large trials testing retatrutide in different populations.

The standout results come from TRIUMPH-4, which ran for 68 weeks:

People on the highest dose achieved an average weight loss of 28.7%
About 90% of participants lost at least 15% of their body weight
About 75% lost at least 20%
About 60% lost at least 25%

A 28.7% average weight loss is unprecedented for any medication. That same 220-pound person would lose about 63 pounds. These numbers start to approach what people achieve with bariatric surgery, but without the operating room.

How Does This Compare to Other Drugs?

Medication	How It Works	Average Weight Loss
Semaglutide (Wegovy)	GLP-1 alone	~15%
Tirzepatide (Zepbound)	GLP-1 + GIP	~22.5%
Retatrutide	GLP-1 + GIP + Glucagon	~28.7%

Each new generation has brought a meaningful jump in effectiveness, and retatrutide represents the biggest leap yet.

What Are the Side Effects?

Like any medication, retatrutide comes with side effects. The good news is that the side effect profile is similar to what we already see with other weight loss injections in this class. The most common issues are GI-related:

Nausea: The most frequently reported side effect, especially during the first few weeks and during dose increases
Diarrhea: Common but usually mild
Vomiting: Less common than nausea
Constipation: Some people experience this instead of or in addition to diarrhea
Decreased appetite: Very common, though this is also how the drug works

Most of these side effects are worst during the dose escalation phase (the first several weeks when the dose is being gradually increased) and tend to improve over time.

Serious side effects were uncommon in clinical trials. Researchers are monitoring for potential concerns including pancreatitis, gallbladder issues, and thyroid effects, which are known class-wide considerations for GLP-1 based drugs.

For a complete breakdown of side effects and management tips, read our retatrutide side effects guide.

When Will Retatrutide Be Available?

This is the question everyone wants answered, and unfortunately, we're still a ways out from seeing retatrutide on pharmacy shelves.

Where Things Stand in 2026

As of early 2026, retatrutide is in Phase 3 clinical trials. Multiple TRIUMPH trials are underway, and results are being reported. However, Eli Lilly has not yet submitted a New Drug Application (NDA) to the FDA.

The Path to Your Pharmacy

Here's how the process typically works and where retatrutide is in that process:

Phase 1 trials: Completed. Tested safety in small groups.
Phase 2 trials: Completed. Tested effectiveness and dosing in medium-sized groups.
Phase 3 trials: Currently underway. Large-scale trials testing effectiveness and safety in thousands of people.
NDA submission: Expected late 2026 or early 2027. Eli Lilly submits all trial data to the FDA.
FDA review: Typically takes 10-12 months (could be faster with priority review).
FDA decision: Most analysts predict a possible approval in late 2027 or 2028.

So realistically, we're looking at roughly 18-24 months before retatrutide could be prescribed. That timeline could shift in either direction depending on trial results and FDA scheduling.

How Is Retatrutide Different from Existing GLP-1 Drugs?

If you're already taking or considering a GLP-1 medication, you might wonder how retatrutide fits into the picture. Here are the key differences:

More Receptors, More Weight Loss

The fundamental difference is the number of hormone receptors the drug targets. Semaglutide hits one (GLP-1). Tirzepatide hits two (GLP-1 and GIP). Retatrutide hits three (GLP-1, GIP, and glucagon). More receptor targets means the drug can influence your metabolism in more ways simultaneously.

Burns More Calories

This is the big differentiator. The glucagon receptor activation in retatrutide increases your body's energy expenditure, meaning you burn more calories throughout the day, even at rest. No currently approved weight loss medication does this.

Potentially Better for Liver Health

Glucagon plays a major role in liver metabolism. Clinical trials have shown that retatrutide dramatically reduces liver fat, potentially more than any other medication in development. This could make it especially valuable for the millions of people with fatty liver disease (MASH/NAFLD).

Same Basic Administration

Despite the more complex mechanism, retatrutide is still a once-weekly injection, just like semaglutide and tirzepatide. The patient experience of taking it would be very similar.

Who Might Be a Good Candidate for Retatrutide?

While retatrutide isn't available yet, we can make educated guesses about who it will be prescribed for based on the clinical trial criteria and how similar drugs are currently prescribed.

Likely Candidates

Adults with a BMI of 30 or higher: This is the standard threshold for obesity
Adults with a BMI of 27 or higher plus at least one weight-related condition: Such as high blood pressure, type 2 diabetes, high cholesterol, or sleep apnea
People who haven't reached their goals with other medications: Retatrutide may be an option for people who plateaued on semaglutide or tirzepatide
People with significant fatty liver disease: The liver health benefits may make retatrutide particularly valuable for this group

Who It Probably Won't Be For

People with a history of medullary thyroid carcinoma or MEN 2: Like all GLP-1 drugs, retatrutide will likely be contraindicated for these conditions
People with a history of pancreatitis: Will likely need careful evaluation
Pregnant or breastfeeding women: Weight loss medications are not recommended during pregnancy
People looking to lose a small amount of weight: This class of medications is intended for clinically significant obesity

Can I Get Retatrutide Now?

You cannot get FDA-approved retatrutide now because it hasn't been approved yet. The only way to access retatrutide currently is through participation in a clinical trial.

You may see some sources online claiming to sell retatrutide. We strongly caution against purchasing retatrutide from unverified sources. Without FDA approval, there's no guarantee that what you're getting is actually retatrutide, that it's been manufactured safely, or that it's the correct dose. The risks of using unverified injectable medications are serious.

What to Do in the Meantime

If you're interested in retatrutide because you want to lose weight, the good news is that highly effective, FDA-approved options are available right now:

Semaglutide (Wegovy): FDA-approved for weight loss, with average results of about 15% body weight reduction
Tirzepatide (Zepbound): FDA-approved for weight loss, with average results of about 22.5% body weight reduction

Starting treatment with one of these medications now means you can begin losing weight and improving your health today, rather than waiting another year or two for retatrutide. And if retatrutide does come to market and proves to be a better option for you, switching at that point is always a conversation you can have with your provider.

The Science Behind the Triple Agonist: Going a Bit Deeper

For those who want a slightly more detailed understanding of how the three receptors work together, here's a deeper look.

GLP-1: Your Brain's "Stop Eating" Signal

GLP-1 receptors are found in several key areas of your body, including your brain's hypothalamus (which controls hunger), your stomach, and your pancreas. When retatrutide activates these receptors:

Your hypothalamus receives stronger satiety signals, reducing hunger and food cravings
Your stomach empties more slowly, keeping you feeling full longer after meals
Your pancreas releases more insulin when needed, improving blood sugar control
Food reward pathways in the brain may be dampened, reducing the emotional pull of food

GIP: Your Metabolic Optimizer

GIP receptors are found in your pancreas, fat tissue, bones, and brain. When activated:

Insulin sensitivity improves, meaning your cells use blood sugar more efficiently
Fat distribution may shift, with reductions in harmful visceral fat (the fat around your organs)
The satiety signals from GLP-1 are amplified
Bone health may be supported (an important consideration during significant weight loss)

Glucagon: Your Fat-Burning Accelerator

Glucagon receptors are concentrated in your liver but are also found in fat tissue and other organs. When activated:

Your liver increases fat oxidation (breaking down stored fat for energy)
Your overall resting metabolic rate increases
Thermogenesis (heat production) increases, burning additional calories
Liver fat decreases significantly

The combination of these three mechanisms creates what researchers describe as a "comprehensive metabolic reset." You eat less because your appetite is genuinely reduced. Your body handles the food you do eat more efficiently. And you burn more of your stored fat for energy. It's addressing obesity from every possible angle.

What About the Cost?

Since retatrutide isn't approved yet, we don't have an official price. However, based on how Eli Lilly prices its other medications and the general landscape of weight loss drugs, we can make some predictions:

Wegovy (semaglutide) has a list price of roughly $1,300-$1,400 per month
Zepbound (tirzepatide) has a list price of roughly $1,000-$1,100 per month
Retatrutide will likely fall somewhere in the $1,000-$1,500 per month range

Insurance coverage, manufacturer savings programs, and potentially compounding options could all affect what you actually pay. For a detailed analysis of expected costs and how to save, check out our retatrutide cost guide.

Frequently Asked Questions

Is retatrutide the same as tirzepatide?

No. Both are made by Eli Lilly and share some similarities, but they're different medications. Tirzepatide targets two receptors (GLP-1 and GIP), while retatrutide targets three (GLP-1, GIP, and glucagon). Retatrutide has shown greater weight loss in clinical trials.

Will retatrutide come as a pill?

Not initially. Retatrutide is being developed as a once-weekly injection. However, Eli Lilly is separately developing oral weight loss medications (like orforglipron), and it's possible an oral version of retatrutide could be explored in the future.

Is retatrutide safe?

Clinical trial data so far shows a safety profile consistent with other incretin-based medications. The most common side effects are GI-related (nausea, diarrhea, vomiting) and tend to be mild to moderate. However, long-term safety data is still being collected. The Phase 3 TRIUMPH program includes dedicated safety studies.

How much weight can I expect to lose on retatrutide?

In clinical trials, the average weight loss at the highest dose was about 24-29% of body weight over 48-68 weeks. Individual results vary. Some people lose more, some less. Factors like starting weight, genetics, diet, and exercise all play a role. For more detail, see our retatrutide weight loss article.

Can I participate in a retatrutide clinical trial?

Possibly. Eli Lilly's TRIUMPH trials are still enrolling at various sites. You can search for active trials at ClinicalTrials.gov by searching for "retatrutide" or "LY3437943." Your healthcare provider may also be able to help connect you with a trial site.

What will retatrutide's brand name be?

Eli Lilly hasn't announced a brand name yet. They'll likely choose one closer to the time of FDA submission or approval. For reference, their previous drug tirzepatide was given two brand names: Mounjaro (for diabetes) and Zepbound (for weight loss). Retatrutide may follow a similar approach.

The Bottom Line

Retatrutide is the most promising weight loss medication currently in development. By targeting three hormone receptors instead of one or two, it produces weight loss results that surpass anything we've seen from a medication before. The Phase 3 TRIUMPH trials are underway, and if all goes well, we could see FDA approval in late 2027 or 2028.

In the meantime, if you're dealing with obesity and want to start treatment now, proven options are available. Talk to one of our physicians about whether semaglutide or tirzepatide might be right for you. There's no reason to wait years for a new drug when effective treatments exist today.

We'll keep this article updated as new trial results come in and as retatrutide moves closer to availability. Bookmark this page and check back for the latest.